Kaveri Pohlman
Stock Analyst at Clear Street
(1.84)
# 3,319
Out of 5,240 analysts
34
Total ratings
34.38%
Success rate
-5.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Maintains: Buy | $104 → $116 | $104.21 | +11.31% | 1 | Apr 7, 2026 | |
| EVMN Evommune | Initiates: Buy | $53 | $23.17 | +128.74% | 1 | Mar 18, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $45 → $70 | $18.27 | +283.14% | 1 | Mar 11, 2026 | |
| ERAS Erasca | Maintains: Buy | $11 → $20 | $10.30 | +94.17% | 1 | Mar 6, 2026 | |
| JANX Janux Therapeutics | Downgrades: Hold | $32 → $12 | $14.51 | -17.30% | 3 | Jan 20, 2026 | |
| PALI Palisade Bio | Initiates: Buy | $12 | $1.85 | +548.65% | 1 | Dec 30, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $61 → $99 | $37.95 | +160.90% | 1 | Dec 9, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $200 | $119.44 | +67.46% | 1 | Dec 5, 2025 | |
| JBIO Jade Biosciences | Initiates: Buy | $25 | $24.71 | +1.17% | 1 | Nov 25, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $11 → $21 | $14.74 | +42.47% | 1 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.81 | +274.22% | 1 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $7.40 | +291.89% | 1 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $46 | $62.69 | -26.62% | 1 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $28.70 | +11.50% | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.97 | - | 4 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $46 → $47 | $27.01 | +74.01% | 3 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $30 | $16.33 | +83.71% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $38 | $11.97 | +217.46% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $5 | $4.75 | +5.26% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.38 | +236.13% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $50.78 | -46.83% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $24.92 | +180.90% | 1 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $6.66 | +80.18% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $8 | $3.74 | +113.90% | 2 | Jul 7, 2022 |
Protagonist Therapeutics
Apr 7, 2026
Maintains: Buy
Price Target: $104 → $116
Current: $104.21
Upside: +11.31%
Evommune
Mar 18, 2026
Initiates: Buy
Price Target: $53
Current: $23.17
Upside: +128.74%
MoonLake Immunotherapeutics
Mar 11, 2026
Maintains: Buy
Price Target: $45 → $70
Current: $18.27
Upside: +283.14%
Erasca
Mar 6, 2026
Maintains: Buy
Price Target: $11 → $20
Current: $10.30
Upside: +94.17%
Janux Therapeutics
Jan 20, 2026
Downgrades: Hold
Price Target: $32 → $12
Current: $14.51
Upside: -17.30%
Palisade Bio
Dec 30, 2025
Initiates: Buy
Price Target: $12
Current: $1.85
Upside: +548.65%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $61 → $99
Current: $37.95
Upside: +160.90%
Palvella Therapeutics
Dec 5, 2025
Initiates: Buy
Price Target: $200
Current: $119.44
Upside: +67.46%
Jade Biosciences
Nov 25, 2025
Initiates: Buy
Price Target: $25
Current: $24.71
Upside: +1.17%
Trevi Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $11 → $21
Current: $14.74
Upside: +42.47%
Nov 13, 2025
Initiates: Buy
Price Target: $18
Current: $4.81
Upside: +274.22%
Oct 22, 2025
Initiates: Buy
Price Target: $29
Current: $7.40
Upside: +291.89%
Sep 17, 2025
Maintains: Buy
Price Target: $46
Current: $62.69
Upside: -26.62%
Jun 25, 2025
Initiates: Buy
Price Target: $32
Current: $28.70
Upside: +11.50%
Aug 1, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.97
Upside: -
Jun 27, 2024
Maintains: Buy
Price Target: $46 → $47
Current: $27.01
Upside: +74.01%
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $16.33
Upside: +83.71%
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $11.97
Upside: +217.46%
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $4.75
Upside: +5.26%
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $2.38
Upside: +236.13%
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $50.78
Upside: -46.83%
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $24.92
Upside: +180.90%
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $6.66
Upside: +80.18%
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $3.74
Upside: +113.90%